Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1986-11-24
|
pubmed:abstractText |
Seventeen patients with acute transmural myocardial infarction and angiographically confirmed complete coronary occlusion were treated with heparin combined with intravenous single-chain urokinase-type plasminogen activator (scu-PA), obtained by expression of the cDNA encoding mature human scu-PA in Escherichia coli. In eight patients, recombinant scu-PA (rscu-PA) was given as a 10 mg bolus followed by 30 mg over 1 hr. Recanalization was obtained in six patients, but with persistent delayed opacification of the vessel in four of these patients. During infusion, a plateau level of rscu-PA antigen in plasma of 3.4 micrograms/ml (median value, range 1.4 to 5.5) was reached. At the end of the infusion the alpha 2-antiplasmin level had decreased to 54% (median, range 22% to 82%) of the preinfusion level, the fibrinogen level to 89% (median, range 26% to 101%), and fibrinogen degradation products (FDPs) to 20 micrograms/ml (median, range 8 to 387). In nine patients, rscu-PA was administered as a 10 mg bolus followed by 60 mg over 1 hr. This resulted in recanalization with normal distal filling of the vessel in seven patients, within 46 +/- 17 min (mean +/- SD). During infusion the concentration of rscu-PA in plasma increased to a median value of 7.4 micrograms/ml (range 4.0 to 13.3). At the end of the infusion the alpha 2-antiplasmin level was 22% of baseline (range 5% to 47%), the fibrinogen level 45% (range 4% to 94%), and the concentration of FDPs 87 micrograms/ml (range 6 to 1034). No significant bleeding or short-term side effects were observed.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Fibrin Fibrinogen Degradation...,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrinogen,
http://linkedlifedata.com/resource/pubmed/chemical/Heparin,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activators,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Urokinase-Type Plasminogen Activator,
http://linkedlifedata.com/resource/pubmed/chemical/alpha-2-Antiplasmin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0009-7322
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
74
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1066-70
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:2429783-Adult,
pubmed-meshheading:2429783-Aged,
pubmed-meshheading:2429783-Female,
pubmed-meshheading:2429783-Fibrin Fibrinogen Degradation Products,
pubmed-meshheading:2429783-Fibrinogen,
pubmed-meshheading:2429783-Heparin,
pubmed-meshheading:2429783-Humans,
pubmed-meshheading:2429783-Infusions, Intravenous,
pubmed-meshheading:2429783-Male,
pubmed-meshheading:2429783-Middle Aged,
pubmed-meshheading:2429783-Myocardial Infarction,
pubmed-meshheading:2429783-Pilot Projects,
pubmed-meshheading:2429783-Plasminogen Activators,
pubmed-meshheading:2429783-Recombinant Proteins,
pubmed-meshheading:2429783-Urokinase-Type Plasminogen Activator,
pubmed-meshheading:2429783-alpha-2-Antiplasmin
|
pubmed:year |
1986
|
pubmed:articleTitle |
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|